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Accepted 20 April 2018Background: Routine heart failure (HF) monitoring and management is in the community but the natural course
of worsening renal function (WRF) and its inﬂuence on HF prognosis is unknown.We investigated the inﬂuence
of routinely monitored renal decline and related comorbidities on imminent hospitalisation and death in the HF
community population.
Methods: A nested case-control study within an incident HF cohort (N=50,114) with 12-years follow-up. WRF
over 6-months before ﬁrst hospitalisation and 12-months before death was deﬁned by N20% reduction in esti-
mated glomerularﬁltration rate (eGFR). Additive interactions between chronic kidney disease (CKD) and comor-
bidities were investigated.
Results: Prevalence of CKD (eGFRb60 ml/min/1.73m2) in the HF community was 63%, which was associatedwith
an 11% increase in hospitalisation and 17% in mortality. Both risk associations were signiﬁcantly worse in the
presence of diabetes. Compared to HF patients with eGFR,60–89, there was no or minimal increase in risk for
mild to moderate CKD (eGFR,30–59) for both outcomes. Adjusted risk estimates for hospitalisation were in-
creased only for severe CKD(eGFR,15–29); Odds Ratio 1.49 (95%CI;1.36,1.62) and renal failure(eGFR,b15); 3.38
(2.67,4.29). The relationship between eGFR and mortality was U-shaped; eGFR, ≥90; 1.32(1.17,1.48), eGFR,15–
29; 1.68(1.58,1.79) and eGFR,b15; 3.04(2.71,3.41). WRF is common and associated with imminent
hospitalisation (1.50;1.37,1.64) and mortality (1.92;1.79,2.06).
Conclusions: In HF, the risk associated with CKD differs between the community and the acute HF setting. In the
community setting, moderate CKD confers no risk but severe CKD, WRF or CKD with other comorbidities iden-
tiﬁes patients at high risk of imminent hospitalisation and death.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Population based1. Introduction
Chronic kidney disease (CKD) is a prevalent comorbidity in heart
failure (HF) affecting approximately half of patients in the general pop-
ulation [1]. In acute HF, reduced renal function consistently doubles the
risk of mortality or more depending on the severity of impairment [2].
Worsening renal function (WRF) is a common feature in the varyingss index; BP, Blood pressure; CI,
Estimated glomerular ﬁltration
t Failure; IHD, Ischaemic heart
liability and freedom from bias
niversity of Leicester, Leicester
. This is an open access article underHF course and treatment, which further increases mortality risk [3].
Much of the current WRF evidence relates to short term change during
acute HF decompensation in selected samples [3]. However, the patho-
physiology, presentation and treatment of WRF differs substantially for
acute and chronic HF [4]. In acute HF, WRF usually occurs as a conse-
quence of intensive, sudden or rapid changes in ﬂuid balance. In con-
trast, WRF in chronic HF is more likely to be over weeks or months [5]
which may have considerably different prognostic implications, but
here the evidence is limited.
In the community setting, HF studies have focused mainly on WRF
during optimisation of HF modifying drugs [6–8]. Short term changes
during HF drug intensiﬁcation however is an unreliable indicator of
WRF, instead reﬂecting an appropriate response to treatment [6,9].
Treatment-related WRF can be temporary and clinically patients may
improve in the longer term [10]. Current HF population studies investi-
gating chronicWRF are limited to reduced ejection fraction in small [11]the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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the range of patients with reduced and preserved ejection fraction or
with the comorbidities commonly encountered in the HF general popu-
lation. Notably CKD is associated with hypertension, ischemic heart dis-
ease and diabetes, through both patho-physiology and drug treatment,
and these combined together might increase the prognostic risk even
more in this population.
In UK primary care, renal function is routinely monitored in HF pa-
tients. Through linkage to hospitalisations andmortality data, our objec-
tives were (i) to investigate the association between renal dysfunction,
its longer term change and imminent hospital admission and death in
the heart failure community setting and (ii) the inﬂuence of other co-
morbidities on these relationships.
2. Methods
The Clinical Practice Research Datalink (CPRD) is a large validated database of
anonymised primary care medical records covering approximately 11% of the UK popula-
tion [14]. Data includes patient demographic information, clinical diagnoses, prescriptions,
laboratory tests and lifestyle information. Linkage to admissions data based on all Hospital
Episode Statistics (HES) and mortality data is available for consenting practices (~60%).
Use of the CPRD database was under licence (protocol 12_162) with approval granted
from the Independent Scientiﬁc Advisory Committee.
2.1. Study population
Incident HF patients aged over 40 years who had minimum 3-years of quality clinical
data recording prior to study entry, were selected by a ﬁrst HF diagnostic code applied in
their CPRD clinical record between January 1st 2002 and March 1st 2012 (Supplementary
Table 1 for code set). The HF code setwas validated by clinicians and shown to have high va-
lidity in CPRD [15]. Time in follow-upwas from the ﬁrst HF code to either the date of the pa-
tient transferring out of practice, the index event, death or the study end (1st January 2014).
2.2. Selection of cases and controls
We conducted two separate nested case-control studies within the incident HF
cohort for the outcomes of: (i) all-cause mortality and (ii) all-cause ﬁrst
hospitalisation after HF diagnosis. A nested case-control design with density sam-
pling of controls was applied to account for the varying nature of renal function, phar-
macology (e.g. neurohormonal antagonists) and other clinical factors that vary over
time. Using this approach, renal function and all covariates are measured for each
case and matched controls, at the same time during follow-up and prior to every
event. Controls are eligible to be selected multiple times and later as a case, meaning
that changes to exposure status are captured along the entire follow-up period. This
closely resembles the programming statements approach to Cox-regression with
time varying covariates and produces unbiased estimates of hazard ratios [16,17].
For each case, up to four controls were randomly sampled from the HF cohort who
were still at risk of the event. Matching was by HF index date (±1month) and duration
of follow-up and the controls were assigned the index date of the case.
2.3. Measurement of renal function
Estimated glomerular ﬁltration rate (eGFR) was calculated using the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) formula [18]. Renal function was based
on the most recent eGFR measure before the outcome dates excluding values recorded
N6-months before hospitalisation (median interval 51 [20 to 100] days) and 12-months
before mortality (median interval 84 [32 to 171] days), as the study focus was on short-
term outcomes. CKD was deﬁned as eGFR b60 ml/min per 1.73 m2. Patients were
categorised into six groups recommended by KidneyDisease: Improving Global Outcomes
(KDIGO) [19]. The categories of renal function were: ≥90 (“high”, stage 1), 60–89 (“mild”,
stage 2), 45–59 (‘mild tomoderate’, stage 3a), 30–44 (‘moderate to severe’, stage 3b), 15–
29 (“severe”, stage 4) and b 15 (“kidney failure” or dialysis, stage 5).
2.4. Worsening Renal Function (WRF)
WRF was calculated as the difference between two eGFR values separated by at least
3-months as a proportion of the baseline value. Previous values exceeding 12-months be-
fore the most recent value for hospitalisation (median interval 118 [62 to 208] days) and
2-years for mortality were excluded (median interval 301 [227 to 393] days). WRF was
then adjusted for the interval time to calculate change in eGFR over 6-months for
hospitalisation and 12-months for mortality. The time-window for mortality was chosen
to investigate longer term eGFR change and to maximise the potential of available data,
however change over a shorter timewas likely to bemore clinically relevant as a potential
prognostic indicator for hospitalisation. WRF was deﬁned as a N 20% reduction in eGFR
[20] and moderate reduction as 6–20% decrease. We also included a category of any in-
crease in eGFR. All categories were compared to a reduction of 5% or less as the reference
group.2.5. Measurement of confounding
Confounders measured most recent to outcome dates were age, sex, Index Multiple
Deprivation (IMD) [21], body mass index (BMI), smoking, alcohol, cholesterol,
haemoglobin, blood pressure (BP), hypertension, ischemic heart disease (IHD), previous
myocardial infarction, atrial ﬁbrillation, diabetes and chronic obstructive pulmonary dis-
ease [1]. The IMD score was ranked into quintiles from lowest to highest deprivation;
smoking and alcohol were categorised into ‘current, previous or never’ and all othermea-
sures retained as continuous variables. Drugmeasures for aspirin, renin angiotensin aldo-
sterone system (RAAS) drugs (angiotensin converting enzyme inhibitors, angiotensin II
receptor blockers), beta-blockers and diuretics were also extracted in the 4-month time-
window before the matched dates. For the hospital linked cohort, models were also ad-
justed for a prior hospital admission in the 0–3months, 3 to 6 months or 6 to 12-months
before the HF index date.
2.6. Statistical analysis
Tables on case or control status for both outcomes and presence ofWRF are presented
to compare study measures. To build the multivariable models, linearity was investigated
using likelihood ratio tests and quadratic extensions were added for any non-linear con-
tinuous variables. For correlated variables with coefﬁcient N 0.5, the most clinically rele-
vant one was selected. Multiple imputations using matching variables and full-
conditional speciﬁcation were performed for themissing data usingMI Impute procedure
in Stata version 13, and analyses were combined using Rubin's rules [22].
Conditional logistic regression was used to estimate odds ratios (OR) for the two out-
comes comparing HF patients with CKD compared to those without, adjusting for all con-
founders. To examine the interaction between CKD and hypertension, diabetes or
ischemic heart disease in HF, we tested whether their observed combined effect (CKD
+ comorbidity) on an outcome was more or less than the sum of their separate effects.
Using the Rothman approach [23], for each CKD and comorbidity pair, we created
dummyvariables for the four possible joint exposure combinations (absence/absence [ref-
erence], presence/absence, absence/presence and presence/presence) (Supplementary
Table 2). We then performed conditional logistic regression for the dummy variables for
each exposure pair in turns. We calculated two measures of additive interaction with
95% conﬁdence intervals; the relative excess risk due to the interaction (RERI) and the
Synergy index (S). The RERI is the difference between the expected risk associated with
joint exposure (calculated by adding the individual observed risks) and the observed
risk of joint exposure. The Synergy index (S) is the proportion of excess risk from joint ex-
posure in the presence of interaction relative to if there was no interaction. Interaction is
indicated where RERI ≠ 0 and/or synergy index ≠ 1 [24].
Next, we compared different CKD stages to reference stage 2 (60–89 ml/min/
1.73 m2). We chose this reference group as opposed to eGFR ≥90 due to the normal
renal decline in older age. WRF and other categories of renal function change were
then compared to the eGFR reference group with b5% decrease. In sensitivity analy-
ses, the models investigating renal change were further adjusted for the ﬁrst and sec-
ond eGFR measure used in the change calculation and the mortality models were
further adjusted for deprivation.
3. Results
3.1. HF population characteristics
There were 50,114 incident HF patients, of whom 26,729(53%) died
during amedian follow-up of 2.6[IQR 0.8–5.0] years. Of the sample with
linked hospital data (n= 30,061), 24,339(81%) experienced a ﬁrst
hospitalisation after their HF index date during a median follow-up of
82[IQR 12–435] days. Cases for both outcomes were older, with more
comorbidities and less HF modifying drugs during follow-up, with a
lower BMI, cholesterol, haemoglobin and blood pressure (Table 1).
Among the hospitalisation cases, 66% had CKD compared to 59% of con-
trols and 20% had a prior hospital admission in the 3 months before
their heart failure index date, compared to 4% of controls. In themortal-
ity cohort, CKD was present in 75% of cases and 62% of controls.
3.2. Chronic kidney disease and outcomes
The relative risk of hospitalisationwas 11% higher andmortality 17%
higher for HF patients with CKD compared to those without (Table 2).
The combined effect of CKD and DM was signiﬁcantly higher than
would be expected by their simple co-occurrence (Supplementary
Table 3). Compared to HF patientswithout CKD or diabetes, the increase
in hospitalisation risk associated with CKD without diabetes was 12%
and with diabetes without CKD was 20%. The expected increase in risk
in the presence of both comorbidities was therefore (12 + 20= 32%).
122 C.A. Lawson et al. / International Journal of Cardiology 267 (2018) 120–127The actual observed increase in risk for HF patients with both CKD and
diabetes compared to the reference group was 49%. This gave a signiﬁ-
cant relative excess risk due to interaction (RERI) between CKD and di-
abetes of 17% (RERI 0.17; 95%CI 0.04,0.29) (see Fig. 1). The synergy
index (S) determines the relative proportion of risk due to interaction
relative to if there was no interaction present. The S of 1.52 (95% CI
1.05,2.2) can be interpreted as 52% excess risk from CKD and diabetes
interaction relative to if there was no interaction present. The higher
risk associatedwith CKD and diabetes thanwould be expectedwas con-
sistent for mortality and further compounded by the presence of ische-
mic heart disease. The observed risk of hospitalisation and mortalityTable 1
HF population characteristics of cases and controls by outcomes.
Characteristics Hospitalisation
Cases (n= 24,339) Controls (n= 86,450)
Age, years 79[72–85] 78[70–84]
Women 11,388(46.8) 42,416(49.1)
IMD quintile 1 (least) 4659(19.1) 17,834(20.6)
2 5597(23.0) 20,928(24.2)
3 5142(21.1) 17,794(20.6)
4 5046(20.7) 17,459(20.2)
5 (most) 3825(15.7) 12,163(14.1)
BMI(Kg/m2) 26.8[23.5–30.6] 27.3[24.2–31.4]
Cholesterol(mmol/L) 4.6 ± 1.2 4.7 ± 1.2
Hb(g/dL) 12.9 ± 1.9 13.4 ± 1.6
Systolic BP(mmHg) 134.1 ± 21.6 136.0 ± 19.8
Diastolic BP(mmHg) 74.7 ± 12 75.9 ± 11.0
Beta blocker 8893(36.5) 35,574(41.2)
ACEi 12,477(51.3) 51,430(59.5)
ARB 3722(15.3) 15,602(18.1)
Spironolactone or Eplerenone 3203(13.3) 10,042(11.6)
Diuretics 17,023(69.9) 62,837(72.7)
Hypertension 13,895(57.1) 48,607(56.2)
IHD 11,197(46) 33,570(38.8)
Atrial ﬁbrillation 8470(34.8) 27,145(31.4)
Previous MI 6171(25.4) 17,499(20.2)
COPD 3230(13.3) 8673(10.3)
DM 5577(22.9) 15,714(18.2)
Smoking status
Yes 2965(12.1) 8831(10.2)
No 10,899(44.8) 40,875(47.3)
Ex 9854(40.5) 34,731(40.2)
Alcohol status
Yes 15,678(64.4) 57,882(67.0)
No 5161(21.2) 17,006(19.7)
Ex 955(3.9) 2975(3.4)
Hospital admission during 1-year prior to CPRD HF index date
0–3 months before 5085(20.9) 3578(4.1)
3–6 months before 2509(10.3) 5878(6.8)
6 to 12 months before 2918(12.0) 10,012(11.6)
eGFR(ml/min/1.73 m2) 52.5 ± 19.9 56.4 ± 18.3
CKD (eGFRb60) 10,429(65.6) 33,523(59.3)
CKD stagea
1: ≥90 547(3.4) 2312(4.1)
2: 60–89 4816(30.9) 20,672(36.6)
3A: 45–59 4456(28.0) 17,403(30.8)
3B: 30–44 3836(24.1) 12,328(21.8)
4: 15–29 1796(11.3) 3571(6.3)
5: b15 341(2.2) 221(0.4)
eGFR change
0–5% decrease (Reference group) 1429(11.6) 6019(14.2)
N20% decrease (WRF) 3166(25.7) 8083(19.0)
6–20% decrease 2757(22.4) 10,211(24.1)
Any % increase 4965(40.3) 18,142(42.7)
Data are number patients(%) or mean ± standard deviation or median[IQR]. IMD, index mu
haemoglobin; BP, blood pressure; ACEi, angiotensin-converting enzyme inhibitor; ARB, angio
chronic obstructive pulmonary disease; eGFR, estimated glomerular ﬁltration rate.
a National Kidney Foundation KidneyDisease OutcomesQuality Initiative(KDOQI) guidelines
most recent value (up to amaximumof 1 year) and a secondvalue between 3months and2 yea
match date using the most recent value (up to a maximum of 6-months) and a second value bassociated with all three comorbidities was 20% and 13% higher than
would be expected by their co-occurrence, respectively.
3.3. CKD stages and outcomes
Compared to the eGFR reference group, there was a graded increase
in risk for both outcomes with increasing CKD stage, starting at stage 3b
and steeply increasing for CKD stage 4 and 5 (Table 2). Of the
hospitalisation cases, 14% had CKD Stage 4/5 compared to 7% controls
which corresponded to an adjusted relative risk increase of
hospitalisation of 49% for stage 4 and 238% for stage 5. Presence ofMortality
Missing n(%) Cases (n= 26,729) Controls (n= 106,916) Missing n(%)
– 83[70–84] 78[76–88] –
– 12,974(48.5) 48,758(45.6) –
3064(18.7) 12,844(20.4)
3708(22.6) 14,381(22.8)
3570(21.8) 13,096(20.8)
3427(20.9) 13,024(20.7)
2613(16.0) 9656(15.3)
9.6 25.4[22.1–29.3] 27.3[24–31.3] 8.9
17.7 4.4 ± 1.2 4.5 ± 1.2 14.4
11 12.2 ± 2.0 13.1 ± 1.8 11.6
0.5 126.9 ± 22.3 132.5 ± 19.9 0.6
0.5 71.1 ± 12 73.9 ± 11.1 0.6
– 12,171(45.5) 62,050(58) –
– 12,207(45.7) 62,166(58.1) –
– 3170(11.9) 19,583(18.3) –
5610(21.0) 18,253 (17.1) –
– 21,574(80.7) 81,709(76.4) –
– 15,403(57.6) 62,055(58.0)
– 13,394(50.1) 51,761(48.4) –
10,210(38.2) 39,238(36.7) –
– 7509(28.1) 28,489(26.7) –
– 4630(17.3) 13,848(13.0) –
– 6714(25.1) 25,248(23.6) –
2.4 1.9
3066(11.8) 11,671(11.1)
12,177(46.7) 48,350(46.0)
10,829(41.5) 45,072(42.9)
10.1 9.2
15,744(66.3) 68,370(70.0)
6730(28.3) 24,600(25.2)
1270(5.4) 4652(4.8)
N/A N/A
34.7 46.3 ± 20.7 54.9 ± 19.6 20.7
– 15,821(74.9) 52,388(61.7) –
464(2.2) 3627(4.3) –
4826(22.9) 28,896(34.0) –
4927(23.3) 24,294(28.6) –
5909(28.0) 19,774(23.3) –
3976(18.8) 7333(8.6) –
1009(4.8) 987(1.2) –
50.6 31.9
– 1912(10.5) 11,522(15.9) –
– 5613(30.7) 13,096(18.0) –
– 3707(20.3) 17,637(24.3)
– 7065(38.6) 30,419(41.9) –
ltiple deprivation(1 = least deprived, 5 =most deprived); BMI, body mass index; Hb,
tensin receptor blocker; IHD, ischaemic heart disease; MI, myocardial infarction; COPD,
. For all-causemortality, changewas calculated over a year before thematch date using the
rs earlier. For all-cause hospital admission, changewas calculated over 6-monthsbefore the
etween 3-months and 1 year earlier.
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corresponded to increases in relative risk of death of 68% for CKD
stage 4 and 204% for stage 5. eGFR values between 45 and 59 ml/min/
1.73 m2 were not associated with increased risk of either outcome.
This group were prescribed higher levels of RAAS drugs, similar to the
eGFR reference group (supplementary tables 4 and 5). Whilst there
was a J-shaped relationship between CKD stages and ﬁrst
hospitalisation, the relationship with mortality was U-shaped (Fig. 2)
with a 32% increase in relative risk for stage 1 CKD(eGFR ≥90) compared
to stage 2 (eGFR 60–89ml/min/1.73m2). In the mortality cohort, com-
pared to the reference group with normal renal function, the CKD stage
1 group were much younger (median age 61 v. 75 years), mostly male
(74% v. 62%) with a high BMI (median 29 v. 27) and higher levels of
smoking (27% v. 13%) and diabetes (32% v. 25%) (Supplementary tables
4).When theCKD stage 1 groupwere further stratiﬁed bymortality out-
come (supplementary table 6), the case group were younger (median
age 65 v. 75 years) and had a much higher prevalence of COPD (33% v.
16%), diabetes (32% v. 25%) and smoking (35% v. 13%), a lower BMI
(26 v. 27) and much lower levels of prescribed RAAS drugs (59% v.
76%) compared to the normal renal function reference group.
3.4. WRF and outcomes
WRF occurred in 26% of HF patients over 6-months before
hospitalisation compared to 19% of controls and the respective ﬁgures
were 31% and 18% in the year before death. Patients with WRF were
more likely to be female, have hypertension or diabetes, and prescribed
more diuretics than those without WRF (Supplementary Table 7). In ad-
justed stepwise analyses, high starting and lowending eGFR and younger
age were associated with WRF before both outcomes. In addition, there
were independent associations betweenWRF andmale status, prescribed
ACEi or ARB or diuretic, ischemic heart disease, and lower BP values for
admission and lower cholesterol and diabetes for mortality (p b 0.01)
(not shown).
Compared to thosewith stable renal function, HF patients withWRF
over 6-months had a 50% relative increase in risk of imminent
hospitalisation (Table 2). This was higher for mortality with WRF over
a year associated with a 92% higher relative risk of death compared to
those with stable renal function. More moderate decrease in renalTable 2
Associations between CKD severity, worsening renal function and outcomes in community HF
First hospitalisation
Odds ratio (95% CI)
Unadjusted Adjust
No CKD (eGFR ≥60)(ref) 1.0 1.0
CKD (eGFR b60) 1.31(1.26–1.36) 1.11(1
CKD stagesa
eGFR mL/min/1.73m2
Stage 1 (60–89)(ref) 1.0 1.0
Stage 2 (≥90) 0.95(0.86–1.06) 0.95(0
Stage 3a (45–59) 1.08(1.02–1.13) 1.02(0
Stage 3b (30–44) 1.29(1.22–1.36) 1.10(1
Stage 4 (15–29) 2.09(1.95–2.25) 1.49(1
Stage 5 (b15) 6.24(5.09–7.65) 3.38(2
Worsening renal functionb
0–5% decrease(ref) 1.0 1.0
N20% decrease (WRF) 1.71(1.58–1.86) 1.50(1
6–20% decrease 1.16(1.07–1.26) 1.11(1
Any % increase 1.20(1.11–1.29) 1.13(1
Adjusted for current age, gender, Hb andHb2, BMI and BMI2, beta blocker, ACEi, ARB, spironolac
BP and systolic BP2, alcohol use and smoking. Hospitalisation further adjusted for prior hospita
a National Kidney Foundation Kidney Disease Outcomes Quality Initiative(KDOQI) guideline
b For hospitalisation, renal change was calculated over 6-months before the match date usin
months and 1 year earlier. For mortality, renal change was calculated over a year before the ma
tween 3months and 2 years earlier.function (6–20%)was only associatedwith a small increase in risk of ei-
ther outcome. Theses associations were independent of the starting or
subsequent eGFR values (Supplementary Table 8). Increase in renal
function was also associated with a 13–22% increase in relative risk of
hospitalisation and death respectively. This group were prescribed less
RAAS inhibitors (74% v. 78%) and had more hypertension (62% v.
60%), AF (39% v. 37%) and diabetes (29% v. 27%) and less IHD (45% v.
56%) than the stable renal function group (supplementary table 7).
4. Discussion
In a national HF population-based cohort of over 50,000 community
patients, CKD was common, but did not increase the risk of
hospitalisation or mortality unless it was severe, or kidney failure was
present. However, the risk associated with CKD increased signiﬁcantly
in the presence of diabetes and ischemic heart disease. Worsening renal
function was also common, occurring in a quarter of all HF patients and
signiﬁcantly increased the risk of imminent hospitalisation within 6-
months or deathwithin 12months. These ﬁndings provide the key prog-
nostic evidence for identifying high risk HF comorbid groups in the com-
munity where most patients are routinely managed and receive ongoing
care.
There are four key clinical implications of ourﬁndings. First,whilst the
high prevalence of CKD in the communityHF populationwas comparable
to hospital [25] and other specialist care settings [26], it did not convey
the same risk of poor outcomes found in more acute settings where HF
decompensation is common [1,27]. In the community setting, mild to
moderate renal dysfunction (CKD stage 3a) did not confer risk of
hospitalisation or death and risks only began to rise steeply at eGFR levels
below 30ml/min/1.73m2. Of note, over 75% of HF patients with stage 3a
and3bCKDwere prescribedACEi or anARB, similar to thosewithout CKD
and similar to specialist HF clinics [28]. These drugs are recommended in
heart failure with reduced ejection fraction (HFrEF) even in the presence
of moderate renal dysfunction [20].Whilst we did not have ejection frac-
tion data available, the high proportion of prescribing indicates good ad-
herence to HF guidelines and that patients with mild to moderate renal
deterioration are well managed in the community.
Second, the associations between CKD stages and mortality had a
more complex U-shape relationship, with an increased risk in CKDpatients.
All-cause mortality
Odds ratio (95% CI)
ed Unadjusted Adjusted
1.0 1.0
.05–1.16) 1.87(1.81–1.94) 1.17(1.12–1.22)
1.0 1.0
.85–1.08) 0.76(0.69–0.85) 1.32(1.17–1.48)
.97–1.08) 1.23(1.17–1.28) 0.99(0.94–1.04)
.03–1.17) 1.80(1.72–1.88) 1.16(1.10–1.22)
.36–1.62) 3.23(3.07–3.40) 1.68(1.58–1.79)
.67–4.29) 6.25(5.65–6.91) 3.04(2.71–3.41)
1.0 1.0
.37–1.64) 2.64(2.48–2.80) 1.92(1.79–2.06)
.02–1.21) 1.27(1.19–1.35) 1.12(1.04–1.20)
.04–1.22) 1.40(1.32–1.48) 1.22(1.15–1.31)
tone or eplerenone, diuretic, IHD, previousMI, hypertension, AF, COPD, cholesterol, systolic
lisation over 3,6 or 12-months and deprivation.
s.
g the most recent value (up to a maximum of 6-months) and a second value between 3-
tch date using the most recent value (up to a maximum of 1 year) and a second value be-
Fig. 1. Additive interaction between CKD and comorbidity combinations -The blue block (bars 1 to 4) represents the risk in the HF reference groupwithout any of the speciﬁed comorbidities present. -The green and the red blocks (bars 2 to 4) show
the risk associatedwith the speciﬁed comorbidities in addition to the reference group. -Bar 4 displays the riskwhen all of the speciﬁed comorbidities are present. The stacked red and green blocks represent the risk that is expectedwhen the speciﬁed
comorbidities are present (or added) together. The purple block shows the actual or observed risk when the speciﬁed comorbidities are present together and represents the risk due to interaction of the comorbidities. This means that the observed
combined effect of the comorbidities on the outcome was more than the sum of their separate effects.
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Fig. 2. Adjusted associations between eGFR categories and outcomes.
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have found similar increases in mortality risk at eGFR ≥90 [29,30],
other low ejection fraction studies focusing on cardiovascular speciﬁc
outcomes have reported a linear relationship between decreasing
renal function and mortality risk [13,31]. This high eGFR and mortality
risk paradox reported in general populations is thought to represent a
false estimation of kidney function due to loss of muscle mass linked
to frailty and predominating more in comorbid groups [32,33]. In our
study the high eGFR mortality case group, compared to the HF group
with normal renal function,were predominantly youngermale smokers
with a lower BMI and muchmore likely to have COPD or diabetes, with
lower prescribing of RAAS drugs. This proﬁle points to the possibility of
hyperﬁltration in early diabetic nephropathy [34], or frailty in end stage
respiratory or cardiac disease. Our community ﬁndings show that very
low and high eGFR levels might be prognostic indicators of a more se-
vere HF group, but that high eGFR levels need to be interpreted cau-
tiously in the context of comorbidity and associated frailty.
Third, our study provides new evidence on the interaction between
CKD and other cardio-renal comorbidities. The risk of both outcomes as-
sociated with CKD and diabetes was signiﬁcantly greater than would be
expected and this was further compounded by ischemic heart disease
(IHD). CKD is a well-known risk factor for IHD which can lead to further
renal deterioration [35] and diabetic nephropathy is one of the most fre-
quent causes of end-stage renal disease [36]. These ﬁndings are impor-
tant because not only do these comorbidities commonly co-occur but
they exacerbate each other, providing the potential for intensiﬁed pro-
gression. CKD and diabetes was present in 18% of patients and over half
of these also had concomitant IHD which indicates important and high
risk groups in HF. Our ﬁndings indicate an important need for shared
management and optimisation of therapies for themost common comor-
bid disease combinations.
Fourth,WRF occurred in 21% of the community HF patients and was
signiﬁcantly associated with increased risk of imminent 6-month
hospitalisation or 12-month mortality. Part explanation of these associ-
ations might relate to the underlying hemodynamic status of the HF
with worsening renal function acting as a pseudo marker of worsening
cardiac function. However, the dose-response relationship between in-
creasing severity ofWRF and higher risk and the adjustment for key fac-
tors including relevant drugs and baseline renal function, suggests
independent associations between WRF and outcomes. Improving
renal function in 40% of the HF sample was also associated with poorer
outcomes, which is consistent with comparable evidence in acute de-
compensated HF [37]. Improved function might reﬂect treatment withdiuretics following right sided cardiac dysfunction and venous conges-
tion but this ﬁnding requires further investigation in the community
setting.
4.1. Strengths and limitations
Our study is one of the largest to date to investigate longitudinal
renal function and change in a population-based community cohort of
newly diagnosed HF patients. The easily accessible routine monitoring
measures of CKD and change offers an important tool for risk stratiﬁca-
tion in the community and potential trigger of earlier interventions. Key
strengths include the large national HF sample, linkage to hospital data
and the use of density sampling that provided the method to measure
WRF in speciﬁc time-windows before hospitalisation and death.
Routinely collected data can be subject to measurement bias [38],
but the CPRD is used as a clinically validated population-based epidemi-
ological database globally [14]. The study focus was on HF prognosis in
the non-specialist community setting, so the deﬁnition of HFwas based
on clinical coding, the quality for which is high [15]. However, lack of
ejection fraction or brain natriuretic peptide data in the CPRD means
that further validation of the study ﬁndings in different HF phenotype
groups would be required. Lack of HF severity indicators in the CPRD
such as ejection fraction and NYHA class means that it was not possible
to disentangle the effects of renal from cardiac dysfunction. In consider-
ing confounders, comorbidities were based on clinical recording which
can be subject to misclassiﬁcation leading to under-ascertainment.
That said, any such misclassiﬁcation is likely to bias the associations to-
wards the null value. There was also some missing data for measures
such as BMI and smoking. We used multiple imputations for some of
these missing data, but we did not impute eGFR values as this was our
exposure of interest. Whilst 80% of patients had at least one eGFR mea-
sure prior to the case-control match dates, only approximately half of
the patients had two measures available and this means that some ex-
posure information was excluded from our analyses. HF management
will have also changed in the 12-year time window of the database,
and tominimise the potential effect of such changes, in our study design
case and controls were matched on calendar time and eGFR and con-
founders were measured before the matched dates.
5. Conclusions
Our large scale study has shown that in the general HF population,
mild to moderately severe CKD does not confer the same increased
126 C.A. Lawson et al. / International Journal of Cardiology 267 (2018) 120–127risks of hospitalisation or mortality found in selected or hospitalised HF
patients. The risk associatedwithCKD signiﬁcantly increases atmore se-
vere renal dysfunction or in the presence of other comorbidities. How-
ever, worsening renal function during the course of HF is common and
identiﬁes HF patients at high risk of imminent hospitalisation and
death. Renal dysfunction is an easily accessible, routinely collected and
important prognostic tool for HF patients in the general population
andwith other comorbidities needs to be added to HF optimal manage-
ment approaches.
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